Arterial stiffness is a pathological manifestation of cumulative vascular damage resulting from various known and unknown vascular risk factors. Central aortic pressure and pulse wave velocity are the two most commonly used and the most informative non-invasive measures of arterial stiffness. Numerous studies have documented incremental value of these measures in a variety of clinical conditions, most notably, hypertension. In hypertensive subjects, assessment of arterial stiffness not only provides incremental information about vascular risk, it also helps in guiding therapeutic decision making and serves as a tool for monitoring response to antihypertensive therapy.
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obesity, family history, age and gender; among others. One major limitation of these risk assessment tools is that while they can successfully predict the probability of an individual developing CVD, they cannot accurately identify the individuals who are actually going to develop CVDs. This is mainly because the relationship between the vascular risk factors and development of atherosclerosis is imperfect, and also because of the fact that the risk assessment tools take into consideration only the known risk factors, leaving room for the yet unknown risk factors to cause vascular damage. This has prompted research into developing modalities for directly identifying vascular damage at a subclinical stage to better guide CVD prevention and treatment strategies. 13 These include flow-mediated dilation, finger plethysmography, digital thermal monitoring, pulse wave analysis (PWA), pulse wave velocity (PWV) assessment, pulse contour analysis, carotid wall distensibility coeffi cient, carotid intima-media thickness (CIMT), [14] [15] [16] [17] [18] [19] ankle brachial index (ABI), 20 ,21 coronary calcium score (CCS), 11, [22] [23] [24] [25] [26] [27] [28] [29] etc.
Hypertension is one of the major risk factors that contribute to the development of CVDs.
30,31 Significant reduction in cardiovascular (CV) mortality due to an effective battle against high blood pressure (BP) may be considered one of the greatest medical success stories of the past century. 32 For these reasons, measurement of brachial BP has become embedded in routine clinical assessment throughout the world and a reduction in the same taken as a surrogate marker for the reduction of the burden of CVDs. 33 However, over the past 20 to 30 years, there has been a significant improvement in our knowledge of vascular hemodynamics and this has dramatically changed the approach to hypertensive patients. There has been an increasing recognition of the value of arterial stiffness as a marker of vascular damage, particularly in patients with HTN. Hypertension is the most important contributor of arterial stiffness and the reverse is also true with arterial stiffness being the most important mechanism responsible for CV damage resulting from HTN. This review summarizes the present evidence supporting the use of arterial stiffness measures, such as PWV and central aortic pressure as predictive markers for subclinical vascular damage in hypertensive subjects and their role in guiding BP management.
Arterial Stiffness
A delicate balance between the structural and cellular components that make up the vascular tree is responsible for proper functioning. Conditions like ageing, HTN, DM, chronic kidney disease (CKD), atherosclerosis and other pathological conditions can disrupt this balance through various mechanisms and lead to reduced arterial distensibility, a condition defined as arterial stiffening.
On a pathological level, arterial stiffness can be described as a sum of (a) passive stiffness 34 As most of these pathophysiological mechanisms are commonly triggered in patients with HTN increased arterial stiffness is a commonly encountered vascular abnormality in hypertensive patients.
Anatomy and Physiology of a Pulse Wave (Figs 1A and B)
Arterial pressure waveform at any point in the vascular tree is a composite of two distinct components: the forward pressure wave and the reflected pressure wave.
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The forward wave is the BP wave originating from the interaction between the left ventricular ejection activity and the mechanical properties of large arteries, while the reflected wave is the wave returning from the peripheries. 
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In healthy subjects the main reflection sites of the CV system are the arterial bifurcations and the terminal arterioles, which define the systemic vascular resistance. In normal vessels, the reflected wave tends to arrive back at the aortic root during diastole and thus helps in maintaining diastolic BP without significantly increasing systolic BP. However, in the stiff arteries, pressure pulse wave travels at faster speed and therefore the reflected wave arrives back at the central arteries earlier, during systole, adding to the forward wave and augmenting the systolic pressure, 47 while diastolic pressure falls. These changes in central aortic systolic BP and diastolic BP are further augmented by the progressive loss of the 'buffer function' of aorta on the cardiac output as the aorta stiffens. 48 The increase in aortic systolic BP increases cardiac afterload whereas the reduction in aortic diastolic BP levels hampers coronary blood flow. 49 Accordingly, central aortic pressure is the main factor determining the development of left ventricular hypertrophy seen with arterial hypertension.
50,51
Measurement of Arterial Stiffness
As mentioned earlier, technological advances have enabled clinicians to measure arterial stiffness noninvasively through various methods. The measurement of PWV and central aortic PWA are generally accepted as noninvasive, robust, and reproducible methods to determine arterial stiffness. 52,53 Carotid artery pressure is often used as a surrogate for aortic pressure because of the close proximity of these arterial sites.
Pulse Wave Velocity
Pulse wave velocity (PWV) is the velocity at which the pressure pulse wave travels along the arterial system. Since the pulse wave travels at a faster speed in the stiffer arteries, higher PWV indicates increased arterial stiffness. 54 Pulse wave velocity is commonly measured using the 'foot to foot method' in which pulse waveforms are recorded at two different points in the vascular system and the time delay between the feet of each pressure waveform is recorded (Fig. 2) . The distance between these two points divided by the time difference provides the PWV within that segment.
Of the various segments of the arterial system, carotidfemoral PWV is considered to be the gold stan dard as it, being closest to the aorta, best reflects aortic stiffness and has the maximum epidemiological evidence-base to support its use. [55] [56] [57] [58] 
Central Aortic Pulse Waveform Analysis
Pulse wave analysis involves identification and analysis of different components of the central pressure waveform. 61 As mentioned earlier, arterial stiffness augments both the forward pulse wave and the reflected wave. The extent of augmentation of systolic pressure in the central aorta provides a composite estimate of wave reflection and systemic arterial stiffness and is commonly expressed as augmentation index (AIx) (Fig. 3) . Augmentation index is the difference between the 2nd and 1st systolic peaks divided by the central aortic pulse pressure (PP) Fig. 2 : 'Foot-to-foot' method for noninvasive measurement of carotid-femoral pulse wave velocity. ∆t, the time delay between the arrival of pulse at common carotid artery and at the femoral artery; ∆L, distance between the two measurement points and expressed as percentage. 62 Central AIx is derived noninvasively from the radial pressure wave using a mathematical fourier transfer function. 63 More importantly, increased arterial stiffness has also been noted in children 88 and young adults 84 and associated with incident coronary artery disease (CAD) 89, 90 and peripheral arterial occlusive disease. 91 Based on the available evidence, it has been suggested that increased arterial PWV can serve as a useful tool for screening for presence of coronary atherosclerosis. 89, 90 However, for this purpose, it is helpful to combine it with CIMT. Presence of both normal brachial-ankle PWV and normal CIMT has been found to have high negative predictive value for excluding coronary atherosclerosis. Conversely, when both PWV and CIMT are increased, there is high probability of co-existing CAD. 89, 90 The assessment of arterial stiffness can also be used for monitoring the impact of various therapeutic measures on vascular structure and function. Several nonpharmacological treatments, such as exercise training, 92 109 showed a greater reduction in CV events among patients treated with a calcium channel blocker HTNJ et al. 114 They found that PWA was a simple and reproducible technique with which to measure PWV and AIx with very little interobserver variability. Recently published data from the atherosclerosis risk in communities study (ARIC) 115 found that the repeatability of PWV was under acceptable parameters for all PWV measures in a multicenter, populationbased study of older adults and supported its use in epidemiologic studies. However, they also recommended that quantifying PWV measurement variation is critical for applications to risk assessment and stratification and eventual translation to clinical practice. Another study 116 comparing the cost effectiveness of noninvasive assessment of central BP against brachial BP for diagnosis of HTN found central BP monitoring to be more cost effective for both men and women across all age groups.
Future directions
A growing body of evidence suggests that central systolic BP and central PP are accurate markers of the actual pressure load imposed on the left ventricle and are better measurements than peripheral systolic BP and peripheral PP. 117 In addition, numerous studies suggest that parameters of central hemodynamics predict the occurrence of CV events independently of brachial BP values.
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For a biomarker to be integrated into clinical practice, it should meet the following criteria: 118 (a) it must differ between subjects with and without outcomes; (b) it must predict future outcomes in prospective studies; (c) it must add predictive information on top of established risk markers; (d) it must be cost efficient; (e) it must reclassify patients' predicted risk to a sufficient extent; and (f) its use must improve outcomes when evaluated in a randomized study. So far, measurement of arterial stiffness and central BP have fulfilled criteria (a) to (d) sufficiently and more research is being published every day supporting value of PWV, PWA and AIx as markers of CV risk. 119, 120 However, more evidence is needed to determine if these markers also satisfy the criteria (e) and (f).
Of particular note is a prospective, randomized, open-label, blinded end point (PROBE) study by Sharman et al 121 which addressed the use of central aortic BP as a guide for treatment. Patients were randomized to treatment decisions that were guided by best-practice usual care for BP (using office BP, home BP, and 24-hours ambulatory BP) or the addition of a central aortic BP intervention (measured using radial applanation tonometry). A key element of the study was the guidelines and recommendations given to the treating practitioners for titration of therapy. The 5 recommendation scenarios describe the combination of central aortic BP with the amlodipine compared with patients treated with the b-blocker atenolol, without any difference being noted in the reduction of brachial systolic BP values between the groups treated. The potential mechanism underlying these differences was explained by the landmark conduit artery functional endpoint (CAFE) study, 106 which was a sub-study of the larger ASCOT trial. It showed that the two antihypertensive regimens had differential effects on peripheral BP and central aortic pressure. A greater decrease in central systolic BP and in central PP occurred in subjects randomized to amlodipine +/-perindopril as compared to those treated with bendroflumetiazide +/-atenolol, in spite of similar reductions in brachial systolic BP. Based on these finding, the authors concluded that the greater reduction in CV events in the group treated with amlodipine/perindopril was likely to be due to a greater effect of these drugs in lowering central systolic BP. A similar finding was seen in the REASON study 103, 107 also, which showed a significant reduction in LV mass and a greater decrease in central pressure after 1 year of treatment with low dose perindopril + in dapamide combination as compared to atenolol. Other studies including the heart outcomes prevention evaluation (HOPE) study 110, 111 and the LIFE study 112, 113 have also shown that the clinical benefit of treatment with ACEIs (ramipril) or ARBs (losartan) extend beyond just reduction in brachial BP only and may be attributed to reduced target organ damage resulting from a reduction in arterial stiffness and central aortic pressure. The results of these studies lend support to the hypothesis that an inadequate reduction in central pressure may be associated with an adverse outcome. To date, antihypertensive drugs have been shown to exert variable effects on PWV and arterial stiffness (Table 1) . Further research work is needed to categorize anti-hypertensive drugs on the basis of their actions on PWV and arterial stiffness.
Reproducibility of Measures of Arterial Stiffness
A screening test should be reliable, reproducible, easy to perform and cost effective to warrant its use in regular clinical practice. One of the first studies analyzing the reproducibility of PWA was published by Wilkinson other BP measures (office, home, 24-hour ambulatory BP) so as to increase, maintain, or decrease the therapy. They concluded that guidance of hypertension management with central BP resulted in a significantly different therapeutic pathway than conventional cuff BP, with less use of medication to achieve BP control and no adverse effects on left ventricular mass, aortic stiffness, or quality of life. However, the implications of these observations with respect to the long-term CVD risk remain to be proven. The 2010 guidelines of the ACC/AHA for assessment of CVD risk in asymptomatic adults 122 did not recommend routine measurement of PWV for CVD risk assessment in asymptomatic adults, mainly on the basis of the lack of evidence supporting the ability of PWV to reclassify risk in asymptomatic adults or general population. Later on, after the publication of few large studies mentioned earlier, the recent 2013 ESH/ESC guidelines for the management of arterial hypertension 56 have recommended measurement of PWV for evaluation of subclinical organ damage in hypertensive patients (recommendation class IIa, Level of Evidence: B), and suggested a cutoff of 10 m/s to discriminate between normal aortic elasticity and aortic stiffening. 123 However, they also state that although the measurement of central aortic BP is of interest in terms of analyses for elucidating mechanisms related to pathophysiology, pharmacology, and therapeutics, further investigations are needed before central aortic BP can be recommended for routine clinical use. Indeed, trials are required to assess the impact of arterial stiffness guided management on hard CVD end points, where subjects are followed up for a longer period. At the same time, it is also important to establish normal ranges of various arterial stiffness parameters for different ethnic groups, a key prerequisite for wider use of these markers in clinical practice. However, as the new research emerges to address these pending issues, the next decade could very well be the decade of "arterial de-stiffening. 
